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Bronchiectasis
 irreversible airway dilation 
 focal or a diffuse 
 cylindrical or tubular (the most common form), 
 varicose,
 cystic.
Cylindrical bronchiectasis with 
the characteristic signet ring sign Varicoid bronchiectasis


ETIOLOGY
Focal
 Obstruction 
 Extrinsic
 lymphadenopathy 
 parenchymal tumor mass 
 Intrinsic 
 airway tumor 
 aspirated foreign body
 scarred/stenotic airway
 bronchial atresia
 Chest imaging (chest x-ray and/or chest CT);
 Bronchoscopy 
ETIOLOGY
Diffuse
 Infectious
 bacterial, TB , fungi
 nontuberculous mycobacterial
 Recurrent aspiration
 Noninfectious
 Immunodeficiency
 Genetic 
 Autoimmune or rheumatologic 
 Miscellaneous
 Yellow nail syndrome
 Traction bronchiectasis  
 postradiation fibrosis 
 idiopathic pulmonary fibrosis
 Idiopathic 25–50%
ETIOLOGY
Diffuse: upper lung fields 
 cystic fibrosis (CF) 
 Postradiation fibrosis 
ETIOLOGY
Diffuse: Lower lung fields 
 Chronic recurrent aspiration 
 esophageal motility disorders like those in scleroderma
 End stage fibrotic lung disease 
 Traction bronchiectasis from IPF 
 Recurrent immunodeficiency-associated infections 
 Hypogammaglobulinemia
ETIOLOGY
Diffuse: midlung fields
 NTM
 Mycobacterium avium-intracellulare complex (MAC)
 Dyskinetic / immotile cilia syndrome
 ABPA
 immune-mediated reaction to Aspergillus damages the bronchial wall
 Congenital
 cartilage deficiency 
 Tracheobronchomegaly (Mounier-Kuhn syndrome) 
 Williams-Campbell syndrome
EPIDEMIOLOGY
Bronchiectasis
 Prevalence  
 Varies greatly with the underlying etiology
 CF in late adolescence or early adulthood
 Atypical CF in adults in their thirties and forties 
 MAC infection 
 nonsmoking women >50 years of age
 incidence of bronchiectasis increases with age
 women > men 
 reactivated tuberculosis
 sequela of granulomatous infection
 increased incidence of non-CF bronchiectasis?
PATHOGENESIS AND PATHOLOGY
Bronchiectasis
 mechanism of infectious bronchiectasis 
“vicious cycle hypothesis,” 
 susceptibility to infection 
 poor mucociliary clearance 
 microbial colonization of the bronchial tree 
result in

Pseudomonas aeruginosa
 colonizing damaged airways 
 Evading host defense mechanisms
 Impaired mucociliary clearance 
pathology of bronchiectasis 
 significant small-airway wall inflammation 
 larger-airway wall destruction as well as dilation
 loss of elastin, smooth muscle, and cartilage 
 release proteases and other mediators
 reactive oxygen species and proinflammatory cytokines
 damage the larger-airway walls  
 airflow obstruction
 Antiproteases
 α1 antitrypsin
 neutralizing the damaging effects of neutrophil elastase 
 enhancing bacterial killing
 α1 antitrypsin deficiency             Bronchiectasis and emphysema 
noninfectious bronchiectasis 
 immune-mediated reactions 
 Sjögren’s syndrome 
 Rheumatoid arthritis
 Traction bronchiectasis a result of lung fibrosis 
 postradiation fibrosis 
 idiopathic pulmonary fibrosis

CLINICAL MANIFESTATIONS
 Productive cough 
 thick, tenacious sputum
 crackles and wheezing on lung auscultation
 clubbing 
 Mild to moderate airflow obstruction 
CLINICAL MANIFESTATIONS
Acute exacerbations of bronchiectasis 
 changes in the nature of sputum production
 increased volume and purulence 
 Fever and new infiltrates, may not be present 
DIAGNOSIS
 Persistent chronic cough and sputum production 
 Consistent radiographic features
DIAGNOSIS
 Chest radiographs lack sensitivity              “tram tracks” 
 Chest CT 
 airway dilation
 “signet-ring sign” 
 lack of bronchial tapering
 bronchial wall thickening 
 Inspissated secretions ( “tree-in-bud” pattern) 
 cystic bronchiectasis 


Bronchiectasis
Bronchiectasis
APPROACH TO THE PATIENT
Bronchiectasis
 clinical history
 chest imaging
 workup to determine the underlying etiology
APPROACH TO THE PATIENT
Focal bronchiectasis 
 Almost always requires bronchoscopy 
 airway obstruction by an underlying mass or foreign body
to 
exclude
APPROACH TO THE PATIENT
Diffuse bronchiectasis 
 analysis for the major etiologies 
 initial focus on excluding CF
 Pulmonary function testing 
TREATMENT
Bronchiectasis
 control of active infection 
 improvements in secretion clearance 
 bronchial hygiene 
 decrease the microbial load within the airways
 minimize the risk of repeated infections
ANTIBIOTIC TREATMENT
 Haemophilus influenzae
 P. aeruginosa 
 acute exacerbations
 7–10 days and perhaps for as long as 14 days
 NTM infection can be difficult
 two sputum samples positive on culture
 one BAL fluid sample positive on culture; 
 a biopsy sample displaying histopathologic features of NTM infection 
 granuloma or a positive stain for acid-fast bacilli 
 one positive sputum culture; + pleural fluid sample positive on culture
 macrolide-sensitive MAC 
 macrolide combined with rifampin and ethambutol
BRONCHIAL HYGIENE
 hydration 
 mucolytic administration
 bronchodilators 
 hyperosmolar agents (e.g.,hypertonic saline), 
 chest physiotherapy (postural drainage,mechanical chest percussion 
 Pulmonary rehabilitation and a regular exercise program
 improved exercise capacity and quality of life
 mucolytic dornase (DNase) 
 CF-related bronchiectasis
ANTI-INFLAMMATORY THERAPY
Glucocorticoids
 inhaled glucocorticoids
 alleviated dyspnea
 decreased need for inhaled β-agonists
 reduced sputum production
 lung function 
 bronchiectasis exacerbation rates 
no significant differences 
oral/systemic
Glucocorticoids  
 Risks of immunosuppression 
 adrenal suppression 
 ABPA
 noninfectious bronchiectasis 
 Rheumatoid arthritis 
 Sjögren’s syndrome
 ABPA 
 oral antifungal agent itraconazole
REFRACTORY CASES
 Surgery  
 resection of a focal area of suppuration
 In advanced cases           lung transplantation 
■COMPLICATIONS
 In more severe cases 
 recurrent infections & repeated courses of antibiotics 
 microbial resistance to antibiotics
 combinations of antibiotics 
 life-threatening hemoptysis 
 intubation 
 identification of the source of bleeding
 protection of the nonbleeding lung
 bronchial artery embolization and, in severe cases, surgery
can 
lead to 
■PROGNOSIS
 Outcomes of bronchiectasis 
 Underlying etiology 
 comorbid conditions 
 frequency of exacerbations 
 specific pathogens involved 
 P. aeruginosa colonization
 clinical, radiographic, and microbial features 
 Assessment of quality of life and disease severity
 FEV1 declining by 50–55 mL per year 
 20–30 mL per year for healthy controls
■PREVENTION
 Reversal of an underlying immunodeficient state 
 administration of gamma globulin for immunoglobulin-deficient 
 vaccination  
 influenza and pneumococcal vaccines
 Smoking cessation
TREATMENT
 After resolution of an acute infection
 in patients with recurrences ( ≥3 episodes per year)
 suppressive antibiotics 
 frequency of exacerbations
 mucus production
 decline in lung function
6–12 
months
antibiotic resistance ?
macrolide-resistant NTM
rule out NTM infection
rule out a prolonged QT interval
TREATMENT
 (1) administration of an oral antibiotic 
 ciprofloxacin daily for 1–2 weeks per month; 
 (2) use of a rotating schedule of oral antibiotics 
 (3) administration of a macrolide antibiotic daily or 3 times/ week 
 anti-inflammatory effects
 reduction of gram-negative bacillary biofilms
 (4) inhalation of aerosolized antibiotics (tobramycin inhalation solution)
 30 days on, 30 days off
 (5) intermittent administration of IV antibiotics ( “clean-outs”) 
 more severe bronchiectasis and/or resistant pathogens

Lung abscess 
 necrosis and cavitation of the lung following microbial infection. 
 single 
 multiple 
 single dominant cavity >2 cm in diameter
ETIOLOGY
 The low prevalence 
 Significant morbidity and mortality 
 primary (~80% of cases) 
 Secondary
ETIOLOGY
Primary lung abscesses 
 Aspiration
 anaerobic bacteria
 absence of an underlying pulmonary or systemic condition
ETIOLOGY
Secondary lung abscesses 
 setting of an underlying condition
 Post obstructive process (bronchial foreign body or tumor) 
 systemic process (e.g., HIV infection or another)
Lung abscesses
 Acute  (<4–6 weeks in duration) 
 Chronic  (~40% of cases) 
EPIDEMIOLOGY
 middle-aged men > middle-aged women
 risk factor for primary lung abscesses is aspiration
 altered mental status
 Alcoholism
 drug overdose,
 Seizures
 bulbar dysfunction
 prior cerebrovascular or cardiovascular events
 neuromuscular disease
 esophageal dysmotility or esophageal lesions (strictures or tumors) 
 gastric distention and/or gastroesophageal reflux
 gingivitis and periodontal disease
Aspiration 
 Pneumonitis develops initially (tissue damage caused by gastric acid
 over a period of 7–14 days, the anaerobic bacteria 
 parenchymal necrosis and cavitation 
 depends on host–pathogen interaction 
 Anaerobes 
 Polymicrobial infections
 synergistically to cause more significant tissue destruction
Primary lung abscess
(usually with risk factors for aspiration)
 Anaerobes 
 Peptostreptococcus spp.,
 Prevotella spp., 
 Bacteroides spp., 
 Streptococcus milleri), 
 microaerophilic streptococci
underlying lymphoma
severe Pseudomonas aeruginosa pneumonia
Secondary Lung Abscesses 
 predisposing factor
 bronchial obstruction from malignancy or a foreign body
 prevents clearance of oropharyngeal secretions,
 leading to abscess development
 underlying systemic conditions
 immunosuppression after bone marrow or solid organ transplantation
 impaired host defense mechanisms 
 opportunistic organisms
 septic emboli
 tricuspid valve endocarditis (often involving Staphylococcus aureus) 
 Lemierre’s syndrome
 infection begins in the pharynx (Fusobacterium necrophorum) 
 spreads to the neck and the carotid sheath (which contains the jugular vein) 
 cause septic thrombophlebitis.
Secondary Lung Abscesses
with underlying immunocompromise
 Staphylococcus aureus
 gram-negative rods 
 Pseudomonas aeruginosa
 Enterobacteriaceae
 Nocardia spp.
 Aspergillus spp.
 Mucorales
 Cryptococcus spp.
 Legionella spp.
 Rhodococcus equi, 
 Pneumocystis jirovecii
Secondary Lung Abscesses 
 Endemic infections 
 Mycobacterium tuberculosis 
 Mycobacterium avium
 Mycobacterium kansasii
 Coccidioides spp
 Histoplasma capsulatum
 Blastomyces spp
 parasites 
 Entamoeba histolytica
 Paragonimus westermani
 Strongyloides stercoralis
Miscellaneous conditions 
 Bacterial pathogen (often S. aureus) after influenza or another viral 
 Actinomyces spp
■PATHOLOGY AND MICROBIOLOGY
Primary Lung Abscesses 
 The dependent segments 
 Posterior upper lobes 
 superior lower lobes
 right lung is affected more commonly 
 often polymicrobial,
 anaerobic organisms 
 Microaerophilic streptococci 
A.P
■PATHOLOGY AND MICROBIOLOGY
Primary Lung Abscesses 
 A putrid lung abscess 
 foul-smelling breath, sputum, or empyema; 
 anaerobic lung abscess
■PATHOLOGY AND MICROBIOLOGY
Secondary Lung Abscesses 
 location of secondary abscesses may vary with the underlying cause
 Pseudomonas aeruginosa and other gram-negative rods 
 fungal infections among immunosuppressed patients 
 immunocompromised hosts 
 unusual organisms 
CLINICAL MANIFESTATIONS
lung abscesses 
 similar to those of pneumonia,
 fevers, cough, sputum production, and chest pain
 a more chronic and indolent presentation anaerobic lung abscesses 
 night sweats, fatigue, and anemia 
 putrid lung abscesses 
 discolored phlegm 
 foul-tasting or foul-smelling sputum
 Due to non-anaerobic organisms, such as S. aureus
 More fulminant course high fevers and rapid progression
physical examination 
 Fevers
 poor dentition, and/or gingival disease 
 amphoric and/or cavernous breath sounds on lung auscultation. 
 digital clubbing 
 absence of a gag reflex 
DIFFERENTIAL DIAGNOSIS
 broad & noninfectious processes that result in cavitary lung lesions
 lung infarction
 Malignancy
 Sequestration
 cryptogenic organizing pneumonia
 Sarcoidosis
 vasculitides and other autoimmune diseases
 granulomatosis with polyangiitis
 lung cysts or bullae containing fluid
 septic emboli (e.g., from tricuspid valve endocarditis). 
 pulmonary manifestations of diseases other than the chest 
 inflammatory bowel disease
 pyoderma gangrenosum
DIAGNOSIS
 chest imaging
 thick-walled cavity with an air-fluid level,
 CT may also yield additional information 
 Malignancy
 distinguish a peripheral lung abscess from a pleural infection
 require urgent drainage

DIAGNOSIS
 more invasive diagnostics (such as transtracheal aspiration) 
 Empirical therapy that includes drugs targeting anaerobic organisms 
 polymicrobial, and culture results may not reflect 
 putrid-smelling sputum 
 anaerobic infection 
DIAGNOSIS
 secondary lung abscess 
 empirical therapy fails
 sputum and blood cultures 
 viruses and fungi
 Bronchoscopy with BAL or protected brush specimen collection
 spillage of abscess contents into the other 
 CT-guided percutaneous needle aspiration
 pneumothorax 
 bronchopleural fistula 
 secondary abscesses, especially in immunocompromised hosts, 
TREATMENT
Lung Abscess
 1940s and 1950s 
 3–4 weeks to as long as 14 weeks
 (1) clindamycin 
 (2) IV-administered β-lactam/β-lactamase combination
 3 - moxifloxacin (400 mg/d PO) 
 Metronidazole is not effective as a single agent: 
 not the microaerophilic streptococci 
TREATMENT
secondary Lung Abscess
 identified pathogen, and a prolonged course 
 if the primary lung abscess fails to improve
 underlying predisposing cause for a secondary lung abscess 
additional 
studies to 
rule out
 10–20% of patients may not respond at all
 continued fevers and progression of the abscess cavity on imaging
 surgical resection 
 percutaneous drainage of the abscess
 An abscess >6–8 cm in diameter is less likely to respond to antibiotic 
 complications of percutaneous drainage
 Bacterial contamination of the pleural space 
 Pneumothorax   
 Hemothorax
COMPLICATIONS
 Larger cavity size 
 Persistent cystic changes (pneumatoceles) 
 Bronchiectasis
 recurrence of abscesses 
 Empyema
 life-threatening hemoptysis
 massive aspiration of lung abscess contents
PROGNOSIS AND PREVENTION
 mortality rates for primary abscesses have been as low as 2%,
 secondary abscesses 75% 
 poor prognostic 
 Age of >60
 presence of aerobic bacteria
 sepsis at presentation
 symptom duration of >8 weeks
 abscess size of >6 cm.
PROGNOSIS AND PREVENTION
 underlying risk factors      prevention of lung abscesses
 Airway protection
 oral hygiene
 minimized sedation 
 elevation of the head of the bed 
 Prophylaxis against certain pathogens in at-risk patients 
 bone marrow or solid organ transplants 
 HIV infection 
APPROACH TO THE PATIENT
Lung Abscess
 For patients with a lung abscess 
 low likelihood of malignancy (smokers <45 years old) 
 with risk factors for aspiration
 empirical treatment and then to pursue further evaluation if therapy does not 
elicit a response
 risk factors for malignancy 
 underlying conditions (especially immunocompromised hosts) 
 atypical presentation, 
 earlier diagnostics should be considered
 bronchoscopy with biopsy or CT-guided needle aspiration. 
 consistent with possible bronchial obstruction. 
 endemic for tuberculosis or patients with other risk factors for tuberculosis 
 induced sputum samples 
Lung abscess
CA-MRSA, oral anaerobes, endemic fungi, M. tuberculosis, atypical mycobacteria
